Just In
- 5 hrs ago Summer Style: 6 Must-Try Colors To Stay Fashionably Cool Like B-Town Divas!
- 6 hrs ago Belgian Man Cleared Of Drunk Driving Because His Body Produces Alcohol Due To A Rare Condition
- 7 hrs ago Amitabh Bachchan's Youthful Avatar In Kalki 2898 AD Is Impressive, Check Actors Who Sported Digital De-Aging!
- 7 hrs ago Full Moon In Scorpio In April 2024: How It Will Affect 12 Zodiac Signs
Don't Miss
- Finance Gold Prices In US: Yellow Metal Rates Recover Amidst Economic Uncertainty, GDP Data In Focus
- News Columbia University Anti-Israel Protests Persist Despite Administration's Ultimatums
- Education West bengal class 12th Result 2024 Tentative Date: West Bengal class 12th 2024 Result Expected Soon on wbresul
- Movies Razakar Review: Makrand Deshpande Film Makes Bold Attempt To Touch Sensitive Topic Of Hyderabad Genocide
- Automobiles Toyota Fortuner Leader Edition – Top Things You Need To Know
- Sports 'I Spend Rs 85 lakh in my holidays': Virender Sehwag tells Adam Gilchrist how he refused BBL offer
- Technology HMD Branded First Set of Android Smartphones Are Here!
- Travel Mumbai Opens BMC Headquarters For Exclusive Heritage Tour
Covaxin's Shelf Life Extended To 12 Months From Date Of Manufacture
The Central Drugs Standard Control Organisation (CDSCO) has approved the extension of Bharat Biotech's COVID-19 vaccine Covaxin's shelf life up to 12 months from the date of manufacture, the vaccine-maker said.
"This approval of shelf life extension is based on the availability of additional stability data, which was submitted to CDSCO. With the shelf life extension, hospitals can now utilise the stock to avoid vaccine wastage", a press release said.
Covaxin is approved for use under the 28-day multi-dose vial policy from Drug Controller General of India and the WHO Emergency Use Listing (WHO EUL).
Covaxin Open Vial is stable at 2 to 8 degrees Celsius for 28 days and not required to be discarded immediately in a day or at the end of immunisation session.
Bharat Biotech said it believes in doing a bit for the environment. The multi-dose vial policy saves money for procurement agencies by reducing the cold chain logistics and management thereby reducing the carbon footprint, costs related to open vial wastage, cold chain distribution, cold chain storage and biomedical waste disposal among others.
"Most importantly, we believe in being environmentally friendly by reducing the quantity of packing materials and single-use plastics that are utilised in vaccines manufacturing, storage, distribution and disposal, '' the company said.
- healthCOVID-19 Vaccines and Heart Attacks: New Studies Show Different Results; What Are They?
- wellnessCorbevax Will Be Allowed As A Booster For Those Fully Vaccinated With Covishield Or Covaxin
- kidsCovid-19 Vaccines For Kids: DCGI Grants Emergency Use Nod To 3 Vaccines For Different Age Group Of Children
- wellnessBooster Dose Of COVID Vaccine Needed To Fight Against Omicron: Study
- wellnessIndia's Covaxin To Be Evaluated As COVID-19 Vaccine Candidate In USA
- healthCovaxin Granted Emergency Use Listing In 13 Nations As On Jan 31 According To WHO: Government
- healthEach Dose Of Covishield, Covaxin Likely To Be Capped At Rs 275 After Getting Regular Market Approval
- healthMedia Reports Stating Vaccine Shortage In Maharashtra Are Not Factually Correct: Govt
- healthGovt's Decision On COVID-19 Vaccination For Children 'Unscientific': Senior AIIMS Epidemiologist
- healthExperts Allay Covaxin Concerns, Say 50% Effectiveness Against Delta-Driven COVID-19 Surge Not Bad
- healthGovernment Nod To Commercial Export Of Covishield, Covaxin In View Of Sufficient Stock
- healthCovaxin Shows 50% Effectiveness Against Symptomatic Covid-19 In Real-World Assessment: Lancet Study